Market Overview - The non-white liquor sector experienced a decline of 0.45% on January 15, with Kuaijishan leading the drop [1] - The Shanghai Composite Index closed at 4112.6, down 0.33%, while the Shenzhen Component Index rose by 0.41% to 14306.73 [1] Stock Performance - Notable gainers in the non-white liquor sector included: - *ST Yedao: Closed at 6.44, up 3.21% with a trading volume of 86,100 shares and a turnover of 54.65 million yuan [1] - ST Xifa: Closed at 10.83, up 2.75% with a trading volume of 54,700 shares and a turnover of 58.89 million yuan [1] - *ST Lanhong: Closed at 9.71, up 1.68% with a trading volume of 31,700 shares and a turnover of 30.79 million yuan [1] - Conversely, Kuaijishan saw a decline of 2.25%, closing at 20.41 with a trading volume of 85,300 shares and a turnover of 175 million yuan [2] Capital Flow Analysis - The non-white liquor sector experienced a net outflow of 5.02 million yuan from institutional investors and 10.70 million yuan from retail investors, while retail investors saw a net inflow of 15.72 million yuan [2] - Key capital flows for selected stocks included: - Jinfeng Wine Industry: Net inflow of 11.50 million yuan from institutional investors, but a net outflow of 6.69 million yuan from retail investors [3] - *ST Yedao: Net inflow of 10.16 million yuan from institutional investors, with a net outflow of 6.46 million yuan from retail investors [3] - ST Xifa: Net inflow of 0.94 million yuan from retail investors, but a net outflow of 0.42 million yuan from institutional investors [3]

证券之星消息，1月9日非白酒板块较上一交易日上涨0.6%，ST西发领涨。当日上证指数报收于4120.43， 上涨0.92%。深证成指报收于14120.15，上涨1.15%。非白酒板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 000929 | *ST兰黄 | 9.70 | -0.10% | 4.14万 | Ir 4024.03万 | | 600573 | 惠泉啤酒 | 11.93 | 0.00% | 9.03万 | 1.08亿 | | 000729 | 咸東啤酒 | 12.20 | 0.25% | 15.78万 | 1.92亿 | | 603779 | 威龙股份 | 6.55 | 0.31% | 5.40万 | 3531.15万 | | 600132 | 重庆啤酒 | 52.39 | 0.33% | 2.07万 | 1.08亿 | | 600616 | 金枫酒业 | 5.41 | 0.37% | 10.63万 | 5735.34万 | | 000869 | 张 裕A | 2 ...

股票代码：000752 股票简称：ST 西发 公告编号：2026-001 2、网络投票时间为：2026 年 1 月 7 日。其中，通过深圳证券交易所交易系统进行网络投 票的具体时间为：2026 年 1 月 7 日上午 9:15 至 9:25、9:30 至 11:30，下午 13:00 至 15:00；通 过深圳证券交易所互联网投票系统进行网络投票的具体时间为 2026 年 1 月 7 日上午 9:15 至下 午 15:00 的任意时间。 （二） 股东会现场会议召开地点：成都市高新区天府大道北段966号天府国际金融中心4 号楼9楼。 （三） 股东会召开方式：本次股东会采用现场表决与网络投票相结合的方式召开。 （四） 股东会的召集人和主持人：本次股东会由公司董事会召集，董事长罗希主持。 （五） 本次股东会的召开符合有关法律、行政法规、部门规章、规范性文件、深圳证券 交易所业务规则和公司章程的规定。 西藏发展股份有限公司 2026 年第一次临时股东会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、会议召开和出席情况 （一） 股东会召开时间： 1、现场会 ...

成都市锦江区东御街 18 号百扬大厦 1101 11F,Square One,No.18 Dongyu St. ,Jinjiang District,Chengdu,PRC 电话/TEL：（028）87747485 传真/FAX：（028）86512848 网址/WEBSITE：www.kangdacdlawyers.com/ 北京 西安 深圳 海口 上海 广州 杭州 沈阳 南京 天津 菏泽 成都 苏州 呼和浩特 香港 武汉 郑州 长沙 厦门 重庆 合肥 宁波 济南 北京康达（成都）律师事务所 关于西藏发展股份有限公司 2026 年第一次临时股东会的法律意见书 康达（成都）股会字【2026】第【0001】号 致：西藏发展股份有限公司 北京康达（成都）律师事务所（以下简称"本所"）接受西藏发展股份有限公司（以 下简称"公司"）的委托，指派本所律师出席公司 2026 年第一次临时股东会（以下简称 "本次会议"）现场会议。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下简称"《股东会规 则》"）、《西藏发展股份有限公 ...

Core Viewpoint - The capital market in Tibet has made significant contributions to the high-quality development of the local economy during the "14th Five-Year Plan" period, with a focus on the dual growth of quantity and quality of listed companies, continuous innovation investment, improved investor return mechanisms, and robust risk prevention measures [1][2]. Group 1: Listed Companies' Performance - During the "14th Five-Year Plan," the number of listed companies in Tibet increased to 22, with a total market value rising from over 200 billion to 320 billion yuan, and 14 companies entering the "100 billion club," accounting for nearly 60% [7]. - The total operating revenue of these companies reached 40.98 billion yuan in the first three quarters of 2025, a year-on-year increase of 4.96%, while net profit attributable to shareholders was 6.63 billion yuan, up 37.2%, significantly outpacing national averages [7]. - The pharmaceutical and non-ferrous metal industries have emerged as the main drivers of regional economic development, with 8 pharmaceutical companies and 3 non-ferrous metal companies leading the way [7]. Group 2: Innovation and R&D - Innovation has been a core strategy for listed companies in Tibet, with R&D expenditures reaching 2.206 billion yuan in 2024, a 53.09% increase from 1.441 billion yuan in 2020, and R&D intensity rising to 4.06%, exceeding the national average by about 2 percentage points [12]. - In the first three quarters of 2025, R&D expenses totaled 1.74 billion yuan, a year-on-year increase of 18.8%, with R&D intensity reaching 4.24, nearly double the national average [12]. Group 3: Investor Returns - Listed companies in Tibet have focused on enhancing investor returns, with cumulative cash dividends during the "14th Five-Year Plan" period amounting to 17.012 billion yuan, a 28.79% increase compared to the "13th Five-Year Plan" [14]. - The stability and predictability of dividends have improved significantly, with companies like Meihua Biological achieving the highest cumulative dividends of 6.218 billion yuan during this period [14][15]. Group 4: Financing and Capital Tools - The capital market in Tibet has diversified financing tools, with direct financing amounts growing from 13.92 billion yuan in 2021 to 25.528 billion yuan in 2024, reflecting a compound annual growth rate of 22.40% [16]. - The issuance of asset-backed securities (ABS) marked a significant milestone, with a local state-owned enterprise issuing 7 ABS products in 2024, achieving a "zero breakthrough" in ABS issuance in Tibet [16]. Group 5: Risk Prevention and Regulation - Regulatory authorities in Tibet have adopted a "zero tolerance" approach to risk prevention, handling 13 cases of capital market violations during the "14th Five-Year Plan," with penalties exceeding 30 million yuan [19]. - The region has maintained a "zero default" status for corporate bonds, with no companies facing delisting risks during this period [19]. Group 6: Future Outlook - Looking ahead to the "15th Five-Year Plan," the capital market in Tibet aims to empower regional economic development through innovation, industrial upgrades, and risk prevention, with a focus on nurturing quality enterprises in sectors like pharmaceuticals and new materials [22].

Market Overview - The non-liquor sector increased by 0.17% compared to the previous trading day, with BaiRun Co., Ltd. leading the gains [1] - The Shanghai Composite Index closed at 3968.84, up by 0.09%, while the Shenzhen Component Index closed at 13525.02, down by 0.58% [1] Stock Performance - BaiRun Co., Ltd. (002568) closed at 21.81, with a rise of 2.11% and a trading volume of 102,200 shares, amounting to a transaction value of 222 million yuan [1] - ST XiFa (000752) closed at 66.01, up by 1.57%, with a trading volume of 26,400 shares [1] - GuYueLongShan (600059) closed at 9.26, increasing by 0.87% with a trading volume of 83,400 shares [1] - Other notable stocks include ZhongXinNiYa (600084) at 5.25 (+0.77%), ZhangYu A (000869) at 20.58 (+0.59%), and XianJing Beer (000729) at 11.23 (+0.45%) [1] Capital Flow - The non-liquor sector experienced a net outflow of 36.52 million yuan from institutional investors, while retail investors saw a net inflow of 54.50 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors withdrawing funds while retail investors increased their positions [2] Individual Stock Capital Flow - Qingdao Beer (600600) had a net inflow of over 9.80 million yuan from institutional investors, while retail investors had a net outflow of 9.96 million yuan [3] - WeiLong Co., Ltd. (603779) saw a net inflow of 4.23 million yuan from institutional investors, but a net outflow of 4.59 million yuan from retail investors [3] - Other stocks like ZhongXinNiYa (600084) and ZhangYu A (000869) also showed varied capital flows, with institutional and retail investors reacting differently [3]

Core Viewpoint - The non-white liquor sector experienced a slight increase of 0.12% on December 25, with Kuaijishan leading the gains. The Shanghai Composite Index closed at 3959.62, up 0.47%, while the Shenzhen Component Index closed at 13531.41, up 0.33% [1]. Group 1: Market Performance - Kuaijishan (601579) closed at 21.10, with a rise of 1.98% and a trading volume of 109,700 shares, resulting in a transaction value of 230 million yuan [1]. - Weilang Co. (603779) saw a closing price of 6.65, up 0.91%, with a trading volume of 60,800 shares [1]. - Zhirun Co. (002568) closed at 21.60, increasing by 0.84%, with a trading volume of 55,200 shares [1]. - The overall non-white liquor sector had a net inflow of 38.61 million yuan from main funds, while retail investors experienced a net outflow of 17.34 million yuan [2]. Group 2: Fund Flow Analysis - Huichuan Beer (600573) had a main fund net outflow of 29.06 million yuan, with a retail net outflow of 13.31 million yuan [3]. - Kuaijishan (601579) recorded a main fund net inflow of 10.01 million yuan, but a retail net outflow of 6.47 million yuan [3]. - Jinfeng Wine Industry (600616) experienced a main fund net inflow of 6.48 million yuan, with a significant retail net outflow of 5.36 million yuan [3].

Group 1 - Jizhi Co., Ltd. plans to acquire at least 51% equity in Pumai Technology through cash payment, aiming to gain control over the company, which is a leading enterprise in the field of robot performance testing and calibration in China [1] - Yaxing Chemical's subsidiary intends to transfer 7.14% equity for 60 million yuan to another fund under the same control, indicating strategic investment movements within the same management group [2] - Weigao Bio's application for clinical trials of subcutaneous human immunoglobulin has been accepted by the National Medical Products Administration, targeting primary immunodeficiency diseases [3] Group 2 - Sentai Co., Ltd.'s controlling shareholder plans to increase shareholding by at least 100 million yuan within 12 months, aiming to enhance confidence in the company's future [4] - Health元's subsidiary has received acceptance for the marketing authorization application of Lecanemab injection, which is intended for moderate to severe plaque psoriasis patients [5][11] - Sunshine Nuohuo has signed a technical development contract for the STC008 injection project, with a total payment of 500 million yuan, indicating significant investment in cancer treatment [6] Group 3 - Hunan YN has been designated as a delivery warehouse for lithium carbonate by the Guangzhou Futures Exchange, enhancing its position in the lithium market [7] - Tianji Co., Ltd. is pushing for the industrialization of lithium sulfide material preparation, although it faces risks in commercialization [8] - Yuandong Bio has received FDA approval for Methylene Blue injection, expanding its product portfolio in the U.S. market [10] Group 4 - Nanshan Aluminum has established a wholly-owned subsidiary in Hainan with an investment of 5 million yuan, focusing on high-end aluminum products [13] - ST Xifa plans to acquire 50% equity in Lhasa Beer, aiming for full ownership, with the transaction currently in the planning stage [14] - Hengrui Medicine's SHR-A1904 injection has been included in the list of breakthrough therapy products, indicating its potential in treating advanced gastric cancer [12] Group 5 - Chengdu Gas is planning to merge three subsidiaries, streamlining operations and enhancing efficiency [26] - Baoli Electric intends to invest 50 million yuan to establish a wholly-owned subsidiary focused on key equipment and solutions in energy storage [27] - Huadian International has successfully put the second unit of its Longkou Phase IV project into commercial operation, marking a significant milestone in its energy production capacity [34]

关于资金占用事项被实施其他风险警示的进展公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 因西藏发展股份有限公司（以下简称"公司"、"上市公司"）原控股股东西藏天易隆兴投资有 限公司（以下简称"天易隆兴"）资金占用事项触及《深圳证券交易所股票上市规则》相关规定 情形，公司股票自 2019 年 4 月 10 日被实行其他风险警示。根据《深圳证券交易所股票上市规 则》相关规定，公司就相关资金占用事项的相关情况公告如下： 一、公司原控股股东资金占用情况 公司 2021 年第三次临时股东大会审议通过了《关于资金占用解决方案的议案》。上市公司 将因资金占用事项对天易隆兴享有的 7,365,468.91 元债权转让予控股股东西藏盛邦控股有限公 司（以下简称"盛邦控股"），盛邦控股已一次性完成转让对价支付，公司原控股股东天易隆兴 对上市公司的资金占用余额 7,365,468.91 元得以清偿。 二、公司时任控股股东及关联方资金占用情况 公司 2025 年第二次临时股东会审议通过了《关于资金占用解决方案的议案》，关于时任控 股股东及关联方占用上市公司及拉萨啤酒资金 331 ...

股票代码：000752 股票简称：ST 西发 公告编号：2025-082 西藏发展股份有限公司 关于筹划重大资产重组的进展公告 资产重组决议后，披露重大资产重组预案或者重大资产重组报告书、独立财务顾问报告及重 组涉及的审计报告等相关中介机构报告，并提交股东会批准。目前公司正在开展涉及本次重 组的相关工作，本次交易的方案及具体事项，应以公司与交易对方最终正式签署的《股权转 让协议》及公司披露的上述相关报告为准。公司将严格按照《上市公司重大资产重组管理办 法》相关法律法规的要求履行有关的决策审批程序和信息披露义务。 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本次筹划交易的基本情况 西藏发展股份有限公司（以下简称"公司"）持有拉萨啤酒 50%股权，为拉萨啤酒控股 股东。为更好地聚焦实业、突出主业、深耕专业领域，公司拟筹划以现金方式收购嘉士伯国 际有限公司（以下简称"嘉士伯国际"）所持有的拉萨啤酒 50%的股权。若本次交易能够顺 利完成，公司将持有拉萨啤酒 100%的股权，有利于提高公司资产的完整性，增强公司的持续 经营能力，不会导致公司财务状况发生重大不利 ...